



### **ViSci (Subsidiary) : Approval to register a patent in Europe**

Tel Aviv (July 17, 2018) – BioLight is pleased to announce that today, its subsidiary ViSci Ltd., ("**ViSci**")<sup>1</sup>, announced it has received approval to register a patent from the European Patent Office (the "**Patent**").

The Patent, which joins patent families protecting ViSci 's Eye-D technology, and its first indication, the VS-101, which is an intraocular implant for controlled and delayed release for the treatment of glaucoma using latanoprost, (the "**Device**" and "**ViSci's Product**") protects the chemical structure of the family of the active ingredient for the treatment of glaucoma in ViSci's product and is intended to strengthen and thicken the protection of the ViSci's product.

The Device, which is in its development and licensing stages for treating glaucoma, is based on technology for which ViSci received an exclusive, worldwide, perpetual license from Novartis LLC. The expiration date of the Patent, after its registration, is on October 29, 2029.

The Patent approval in Europe is added to the registration of a patent parallel to technology in the United States, including other patents in the United States related to said technology and the ViSci Device - and are protected under said ViSci's exclusive license, thereby strengthening its intellectual property and competitive position. The completion of registration of the Patent is subject to the payment of the fee, as customary.

---

<sup>1</sup> Holding via XL Vision Sciences Ltd., 97% of the issued and share capital of ViSci.